Every 10-Q that Absci Corporation (ABSI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ABSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABSI filings page.
Absci Corporation reported continued operating losses while advancing its AI-driven biologics pipeline in the quarter ended June 30, 2026. Partner program revenue declined to $0.3 million for the quarter and $0.5 million for the first half of 2026, down sharply from 2025 due to milestone timing and program mix. Net loss widened to $33.2 million for the quarter and $62.8 million year-to-date, driven mainly by higher research and development spending as lead antibody ABS-201 progresses through clinical development.
Absci strengthened its balance sheet with a June 2026 public equity offering that raised approximately $93.6 million net and additional at-the-market sales, bringing cash, cash equivalents and marketable securities to $201.1 million as of June 30, 2026. Management believes this provides funding for at least 12 months. The company highlighted its AI-native Integrated Drug Creation platform and early clinical progress of ABS-201, including positive interim Phase 1 safety data and a long estimated half-life supporting infrequent dosing, while emphasizing that it remains in early stages with no milestone or royalty revenue yet realized.
Absci Corporation reported a net loss of $29.6 million for the three months ended March 31, 2026, as it continues to invest in its AI‑driven antibody pipeline. Partner program revenue was $0.2 million, down sharply from $1.2 million a year earlier due to milestone timing and program mix.
Research and development expenses rose to $19.3 million, reflecting higher external preclinical and clinical spending on lead candidate ABS-201 and broader platform work. Selling, general and administrative costs edged down to $9.1 million, while depreciation and amortization fell to $2.7 million as certain lab equipment was retired.
Cash, cash equivalents and marketable securities totaled $125.7 million as of March 31, 2026, against an accumulated deficit of $654.4 million. The company raised $8.0 million in net proceeds via its at‑the‑market equity program and continues to expect significant ongoing spending on clinical development and its Integrated Drug Creation platform.
Absci Corporation reported third‑quarter 2025 results. Partner program revenue was $0.378 million, down from $1.701 million a year ago, reflecting milestone timing and program mix. The company posted a net loss of $28.7 million (basic and diluted loss per share $0.20) on total operating expenses of $30.5 million, including $19.2 million in R&D. For the first nine months, revenue was $2.15 million and net loss was $85.6 million.
Liquidity remained solid with $152.5 million in cash, cash equivalents and marketable securities as of September 30, 2025. The company strengthened its balance sheet in 2025 through a $20.0 million PIPE with AMD, a July offering yielding $46.7 million in net proceeds, and $35.7 million via a prior ATM program. Shares outstanding were 150,371,531 as of October 31, 2025.
Program updates: ABS‑101 Phase 1 in healthy volunteers showed extended half‑life versus first‑generation anti‑TL1A programs with a favorable safety profile; Absci plans to seek a partner after trial completion. ABS‑201 received HREC approval in Australia, with first dosing targeted for December 2025. A subsequent event settled Totient contingent consideration for approximately $7.6 million and released $8.7 million from escrow.
Absci Corporation reported reduced partner program revenue and higher research spending while advancing its AI-driven antibody pipeline. Revenue was $0.6 million for Q2 and $1.8 million for the six months ended June 30, 2025, down from $1.3 million and $2.2 million in the prior-year periods, respectively. Research and development expense rose 34% year-over-year to $36.8 million for the six months ended June 30, 2025, driven primarily by advancement of drug creation and external preclinical and clinical costs.
The company recorded a net loss of $30.6 million for the quarter and $56.9 million for the six months, with basic and diluted net loss per share of $0.45 for the six months. Cash, cash equivalents and short-term investments totaled $117.5 million at June 30, 2025. Subsequent equity raises after quarter-end generated net proceeds of approximately $60.6 million including an ATM sale and a public offering; Absci also completed a $20.0 million PIPE strategic collaboration with AMD in January 2025. The company initiated dosing in a Phase 1 study of ABS-101 in May 2025 and expects interim and IND-related milestones for ABS-101 and ABS-201 in 2025-2026. Partner revenue remained concentrated, with two partners contributing ~99% of Q2 partner revenue.